Biomotion Sciences Warrant

Silexion Therapeutics Corp is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems for malignant solid tumors. Its proprietary LODER delivery platform is used in its product candidates: SiG12D-LODER, which has completed pre-clinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, in pre-clinical studies for prostate cancer; and GBM-LODER, in pre-clinical studies targeting Glioblastoma Multiforme, a malignant primary brain tumor. The company collaborates with Evonik Corporation on an advanced siRNA formulation to enhance cancer treatment. Founded in 2008, Silexion Therapeutics Corp is headquartered in Jerusalem, Israel.